CVS Health Reports Strong Fourth Quarter And Full Year Profit Growth For 2015; Confirms 2016 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
FBR Still Impressed with CVS Health (CVS) Following Inline Q4 Results; Affirms at 'Outperform'
February 9, 2016 2:34 PM ESTFBR & Co. reaffirms its Outperform rating and $120 price target on CVS Health (NYSE: CVS) following the retail pharmacy giant's Q4 report earlier Tuesday.
Analyst Steven Halper noted that revenue increased 11 percent and was inline with expectations, as was the company's quarterly... More
Leerink Partners Continues to View CVS Health (CVS) as a High Quality Stock - Reiterates Outperform
February 9, 2016 2:07 PM ESTLeerink Partners reiterated an Outperform rating on CVS Health (NYSE: CVS), and cut the price target to $110.00 (from $125.00), following the company's 4Q earnings report and conference call. On the call management highlighted that total specialty revenue grew +32% y/y, total gross PBM wins... More
